Ardelyx, Inc., a biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for patients with gastrointestinal and renal diseases. Founded in 2007, Ardelyx has made significant strides in the industry, particularly with its focus on unique mechanisms of action that address unmet medical needs. The company’s flagship product, tenapanor, is designed to treat conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphataemia in patients with chronic kidney disease. Ardelyx's commitment to scientific excellence and patient-centric solutions has positioned it as a notable player in the biopharmaceutical landscape. With a robust pipeline and a focus on advancing healthcare, Ardelyx continues to make impactful contributions to the industry.
How does Ardelyx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ardelyx, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ardelyx, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year. As such, there are no specific figures regarding their total emissions or breakdowns by Scope 1, 2, or 3. Additionally, the company has not outlined any formal reduction targets or commitments to the Science Based Targets initiative (SBTi). Despite the absence of emissions data and reduction initiatives, Ardelyx, Inc. is actively engaged in climate-related efforts as part of its corporate responsibility. The company is committed to understanding and managing its environmental impact, although specific details on their climate strategies or future commitments have not been disclosed. As the industry increasingly prioritises sustainability, Ardelyx, Inc. may consider establishing measurable targets and reporting frameworks to align with best practices in climate action.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ardelyx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

